Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis

R A Rudick1, R M Ransohoff, R Peppler

  • 1Department of Neurology (Mellen Center), Cleveland Clinic Foundation, OH 44106, USA.

Annals of Neurology
|October 1, 1996
PubMed
Summary

Interferon-beta-1a increases interleukin-10 in relapsing-remitting multiple sclerosis patients, suggesting a mechanism for its therapeutic effects. This finding may inform treatments for other autoimmune diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of <i>FASN</i> gene polymorphism on milk production traits in Bangladeshi cattle: Insights from mutant protein function.

Iranian journal of veterinary research·2025
Same author

Invisible Struggles: Exploring Challenges Faced by Women With Amputation in India.

Canadian prosthetics & orthotics journal·2024
Same author

Abdominal wall reconstruction (AWR) for post-trauma laparotomy ventral hernia and follow-up assessment of functional quality of life (QOL): experience of a level-1 trauma centre in India.

Hernia : the journal of hernias and abdominal wall surgery·2024
Same author

Pruritic papules and nodules as sign of persistent scabies infestation despite treatment according to current guidelines evidence for treatment resistance to ivermectin, benzylbenzoat and permethrin proven by videomicroscopy.

IDCases·2023
Same author

[Itchy skin changes after spending time outdoors].

Dermatologie (Heidelberg, Germany)·2022
Same author

[Therapy-resistant ulcerative plaque on the penis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2021

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Interferon-beta (IFN-β) effectively reduces relapses and disability progression in relapsing-remitting multiple sclerosis (RRMS).
  • The precise mechanism underlying IFN-β's clinical efficacy in RRMS remains largely unknown.
  • This study investigated the hypothesis that IFN-β's immunoregulatory properties contribute to its therapeutic benefits.

Purpose of the Study:

  • To determine the effect of interferon-beta-1a (IFN-β-1a) on the expression of interleukin-10 (IL-10).
  • IL-10 is a key cytokine known for its potent inhibition of cell-mediated immune responses.
  • Investigate potential therapeutic mechanisms of IFN-β-1a in multiple sclerosis.

Main Methods:

  • Cultured peripheral blood mononuclear cells (PBMCs) from healthy individuals and RRMS patients were treated with IFN-β-1a in vitro.

Related Experiment Videos

  • Interleukin-10 messenger RNA (mRNA) and protein levels were measured.
  • Serum IL-10 levels were assessed in RRMS patients following intramuscular injections of IFN-β-1a at different dosages (6x10^6 IU vs. 12x10^6 IU).
  • Transforming growth factor-beta (TGF-β) mRNA levels were also monitored to assess specificity.

    • Main Results:

    • IFN-β-1a induced significant accumulation of IL-10 mRNA and increased protein secretion in cultured PBMCs from both healthy subjects and RRMS patients.
    • Intramuscular administration of IFN-β-1a led to elevated serum IL-10 levels in RRMS patients at 12 and 24 hours post-injection.
    • Higher IFN-β-1a doses (12x10^6 IU) resulted in greater IL-10 increases compared to lower doses (6x10^6 IU).
    • IFN-β-1a treatment did not affect TGF-β mRNA levels, indicating a specific effect on IL-10.

    Conclusions:

    • Upregulation of interleukin-10 is a potential mechanism mediating the therapeutic effects of interferon-beta-1a in relapsing-remitting multiple sclerosis.
    • These findings suggest that targeting IL-10 pathways could be beneficial for RRMS treatment.
    • The immunomodulatory effects of IFN-β-1a on IL-10 have implications for the broader therapy of autoimmune diseases.